NZ617072B2 - Adjuvanted rabies vaccine with improved viscosity profile - Google Patents
Adjuvanted rabies vaccine with improved viscosity profile Download PDFInfo
- Publication number
- NZ617072B2 NZ617072B2 NZ617072A NZ61707212A NZ617072B2 NZ 617072 B2 NZ617072 B2 NZ 617072B2 NZ 617072 A NZ617072 A NZ 617072A NZ 61707212 A NZ61707212 A NZ 61707212A NZ 617072 B2 NZ617072 B2 NZ 617072B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- rabies
- composition
- virus
- vector
- vaccine
- Prior art date
Links
- 229960005486 vaccines Drugs 0.000 title claims abstract description 106
- 206010037742 Rabies Diseases 0.000 title claims description 86
- 230000001976 improved Effects 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 84
- 239000002671 adjuvant Substances 0.000 claims abstract description 71
- 230000000240 adjuvant Effects 0.000 claims abstract description 69
- 229920001661 Chitosan Polymers 0.000 claims abstract description 45
- 230000003612 virological Effects 0.000 claims abstract description 25
- 230000028993 immune response Effects 0.000 claims abstract description 22
- 230000002163 immunogen Effects 0.000 claims abstract description 21
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 230000001965 increased Effects 0.000 claims abstract description 14
- 230000002238 attenuated Effects 0.000 claims abstract description 10
- 230000001681 protective Effects 0.000 claims abstract description 5
- 241000700618 Vaccinia virus Species 0.000 claims description 32
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 11
- 241000282330 Procyon lotor Species 0.000 claims description 9
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 8
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 8
- 241000700663 Avipoxvirus Species 0.000 claims description 4
- 101700030336 GLYCP Proteins 0.000 claims description 4
- 102100011242 THBS1 Human genes 0.000 claims description 4
- 101710041009 THBS1 Proteins 0.000 claims description 4
- 101700087068 VGLG Proteins 0.000 claims description 4
- 101700075237 gG Proteins 0.000 claims description 4
- 108010003398 Rabies virus glycoprotein G Proteins 0.000 claims description 3
- 230000000052 comparative effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002633 protecting Effects 0.000 claims description 2
- 229920000023 polynucleotide Polymers 0.000 description 40
- 239000002157 polynucleotide Substances 0.000 description 40
- 210000004027 cells Anatomy 0.000 description 33
- 241000282335 Procyon Species 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 31
- 108090000288 Glycoproteins Proteins 0.000 description 27
- 102000003886 Glycoproteins Human genes 0.000 description 27
- 239000000427 antigen Substances 0.000 description 27
- 102000038129 antigens Human genes 0.000 description 27
- 108091007172 antigens Proteins 0.000 description 27
- -1 dextran sulfate Chemical compound 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 22
- 239000003921 oil Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- 150000002500 ions Chemical class 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 239000000356 contaminant Substances 0.000 description 14
- 238000003780 insertion Methods 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 241000282421 Canidae Species 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 229920001850 Nucleic acid sequence Polymers 0.000 description 11
- 230000002708 enhancing Effects 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 230000001900 immune effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- 229940079593 drugs Drugs 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 241000229754 Iva xanthiifolia Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001402 polyadenylating Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 5
- 241000178270 Canarypox virus Species 0.000 description 5
- 241000701157 Canine mastadenovirus A Species 0.000 description 5
- 208000000666 Fowlpox Diseases 0.000 description 5
- 241000598171 Human adenovirus sp. Species 0.000 description 5
- 210000000214 Mouth Anatomy 0.000 description 5
- 208000007089 Vaccinia Diseases 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 210000003501 Vero Cells Anatomy 0.000 description 5
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 5
- 230000002458 infectious Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001737 promoting Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000282324 Felis Species 0.000 description 4
- 241000700662 Fowlpox virus Species 0.000 description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 4
- 229920002459 Intron Polymers 0.000 description 4
- 108050006987 Poxvirus Proteins 0.000 description 4
- 229960003127 Rabies Vaccines Drugs 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 230000003253 viricidal Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- WXNRAKRZUCLRBP-UHFFFAOYSA-N 2-[3-(dioctadecylamino)propyl-(2-hydroxyethyl)amino]ethanol Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 3
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 229920001405 Coding region Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000266847 Mephitidae Species 0.000 description 3
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- 229920000320 RNA (poly(A)) Polymers 0.000 description 3
- 101710043164 Segment-4 Proteins 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine Kinase Proteins 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- 101700038759 VP1 Proteins 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000120 cytopathologic Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 101700005460 hemA Proteins 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001888 polyacrylic acid Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 235000008954 quail grass Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 2
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 2
- 229950010555 AVRIDINE Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229960001631 Carbomer Drugs 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108091006011 G proteins Proteins 0.000 description 2
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 2
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282375 Herpestidae Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100013525 MARCOL Human genes 0.000 description 2
- 101710003730 MARCOL Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 229940051027 Pasteurella multocida Drugs 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000700638 Raccoonpox virus Species 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- IJCWFDPJFXGQBN-BIFNRIDTSA-N Sorbitan tristearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-BIFNRIDTSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 229940035893 Uracil Drugs 0.000 description 2
- 241000282487 Vulpes Species 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical class CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2R)-2-[(3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 2
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 229960000074 biopharmaceuticals Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001146 hypoxic Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (Z)-octadec-9-enoate Chemical class OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-M 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC([O-])=O XDOFQFKRPWOURC-UHFFFAOYSA-M 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(Z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- HRURHIPHZVFLTA-UHFFFAOYSA-N 2-[2-[3,4-bis(2-methoxyethoxy)oxolan-2-yl]-2-(2-methoxyethoxy)ethoxy]ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCOCC(OCCOC)C1OCC(OCCOC)C1OCCOC HRURHIPHZVFLTA-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101700018766 ALR1 Proteins 0.000 description 1
- 210000002383 AT1 Anatomy 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000963007 Anelosimus may Species 0.000 description 1
- 206010002515 Animal bite Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Bute hydrocarbon Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 101700086511 CAV2 Proteins 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- 244000224127 Camellia kissi Species 0.000 description 1
- 235000014016 Camellia kissi Nutrition 0.000 description 1
- 241000282470 Canis latrans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000271560 Casuariidae Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 240000008365 Celosia argentea Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Clearol Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 102100000789 DES Human genes 0.000 description 1
- 101700016969 DOK3 Proteins 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229960000633 Dextran Sulfate Drugs 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 241000283075 Equus hemionus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 101710004784 GFER Proteins 0.000 description 1
- 102100014519 GPNMB Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000606831 Histophilus somni Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 210000003000 Inclusion Bodies Anatomy 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 210000004731 Jugular Veins Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-Glutamic acid Natural products OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710011281 MDV056 Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 210000002850 Nasal Mucosa Anatomy 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N Neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229940099678 Norco Drugs 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 241000765083 Ondina Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 101710016786 P/C Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010049025 Persistent generalised lymphadenopathy Diseases 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 102000011587 Polyproteins Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000196435 Prunus domestica subsp. insititia Species 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 108010012057 RNA Replicase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101710033747 S6 Proteins 0.000 description 1
- 229940057429 SORBITAN ISOSTEARATE Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 241000168914 Strepsirrhini Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- 241000288940 Tarsius Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 210000001578 Tight Junctions Anatomy 0.000 description 1
- 229920001949 Transfer RNA Polymers 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 101700012273 UL43 Proteins 0.000 description 1
- 241000555295 Urocyon cinereoargenteus Species 0.000 description 1
- 101700021643 VP4A Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1R)-1-[(2S,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- IYFATESGLOUGBX-NDUCAMMLSA-N [2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-NDUCAMMLSA-N 0.000 description 1
- LWZFANDGMFTDAV-IOVMHBDKSA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O LWZFANDGMFTDAV-IOVMHBDKSA-N 0.000 description 1
- IYFATESGLOUGBX-CBOZIWPYSA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O IYFATESGLOUGBX-CBOZIWPYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229960003942 amphotericin B Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000001147 anti-toxic Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 101710028940 dadB Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000001586 eradicative Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 108060002873 feoA Proteins 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 238000010358 genetic engineering technique Methods 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003232 mucoadhesive Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 239000010691 naphtenic oil Substances 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 229920002973 ribosomal RNA Polymers 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 230000002104 routine Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 108091007206 transmembrane glycoprotein Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Disclosed is a single-dose adjuvanted Rabies virus vaccine composition comprising an attenuated recombinant Orthopox or Avipox viral vector and a methylated chitosan derivative adjuvant, wherein the vector is capable of expressing in an animal host one or more Rabies virus immunogens, and wherein the presence of the adjuvant is associated with both increased viscosity, and increased protective efficacy against subsequent experimental or natural challenge with a virulent Rabies virus, as compared to an otherwise equivalent composition wherein the adjuvant has been omitted. Also disclosed is uses and methods of eliciting immune responses in animals. e presence of the adjuvant is associated with both increased viscosity, and increased protective efficacy against subsequent experimental or natural challenge with a virulent Rabies virus, as compared to an otherwise equivalent composition wherein the adjuvant has been omitted. Also disclosed is uses and methods of eliciting immune responses in animals.
Description
TITLE OF THE INVENTION
Adjuvanted Rabies Vaccine with Improved Viscosity Profile
INCORPORATION BY REFERENCE
This application claims priority to US. provisional patent application No. 61/477,548, filed April
, 2011, the disclosure of which is herein incorporated by reference in its entirety.
FIELD OF THE INVENTION
The present invention relates to adjuvanted rabies vaccines having improved viscosity profiles.
BACKGROUND
Rabies is a disease that can occur in all warm-blooded species and is caused by rabies virus.
Infection with rabies virus followed by the outbreak of the clinical features in nearly all ces results
in death of the infected species. In , the USA and Canada wild life rabies still exists and is an
important factor in the cause of most human rabies cases that occur. On the other hand, urban rabies
constitutes the major cause of human rabies in developing countries.
Rabies virus is a non-segmented ve-stranded RNA virus of the Rhabdoviridae .
Rabies virus s are composed of two major structural components: a nucleocapsid or
cleoprotein (RNP), and an envelope in the form of a bilayer membrane surrounding the RNP
core. The infectious component of all Rhabdoviruses is the RNP core which consists of the RNA
genome encapsidated by the nucleocapsid (N) protein in combination with two minor proteins, i.e.
RNA-dependent RNA-polymerase (L) and phosphoprotein (P). The membrane surrounding the RNP
core consists of two proteins: a trans-membrane glycoprotein (G) and a matrix (M) protein located at
the inner site of the membrane.
The G protein, also referred to as spike protein, is responsible for cell attachment and
membrane fusion in rabies virus and additionally is the main target for the host immune system. The
amino acid region at position 330 to 340 (referred to as antigenic site III) of the G protein has been
identified to be responsible for the virulence of the virus, in particular the Arg residue at position 333.
All rabies virus strains have this nce determining antigenic site III in common.
L V-RG® was developed as an alternative rabies vaccine by Merial, Ltd. As an
alternative rabies vaccine that proved to have the unique and novel attribute of being ive by the
oral route wed by Mackowiak et al., Adv Vet Med. 1999;41:571-83). The vaccine comprises a
modified live vaccinia virus containing the rabies surface glycoprotein gene inserted in its genome. The
first experimental use of the recombinant vaccine in wildlife was initiated in Europe. The vaccine was
contained within a plastic sachet surrounded by an edible bait and deployed into areas known to
contain rabies-infected red fox populations. These campaigns ed in a dramatic reduction in
rabies cases in red foxes and the use of RABORAL V-RG® was considered a success. L V-
RG® was also found to be ive in g a reduction in rabies in raccoons, coyotes and red
foxes (reviewed by Mackowiak et al., Adv Vet Med. 1999;41:571-83), as well as skunks and
mongooses (U82005/0282210A1, Maki JL et al, Merial Limited; Grosenbaugh DA, Maki JL et al. J
Wildlife Dis 2007;43(1):124—8.).
Despite the s of oral vaccination of wildlife, Rabies continues to pose a significant
40 health threat, killing over 55,000 people ly and necessitating prophylactic treatment of over 15
million people post-exposure each year (WHO: Rabies vaccines). One of the goals of the USDA-
APHlS Wildlife Services National Rabies Management Program (WS NRMP) has been to control and
eventually eliminate terrestrial rabies in the United States. In contrast to some other parts of the world,
the primary oir for the virus in the United States is wildlife. In an attempt to achieve rabies
eradication, oral rabies es are distributed by hand and aircraft in most states east of the
chian Mountains as well as portions of Ohio, a, and Texas. It has been estimated that a
vaccination rate of 70% is considered sufficient to break disease transmission cycles (Hethcote, HW et
al. 1978). Presently, it is estimated that Oral Rabies Vaccination (ORV) programs in the US.
successfully vaccinate only 30% of raccoons (Slate, D. et al. 2009), while vaccination rates have been
iently high to ate gray fox and canine rabies in foxes and coyotes, respectively in Texas
(Fearneyhough, MG et al., 1998; Sidwa, TJ et al., 2005).
The ORV program led by WS NRMP currently uses the vaccine, RABORAL V-RG® (Merial
Ltd., Athens, Georgia, described above) in its vaccination campaigns. Currently, RABORAL V-RG® is
delivered in a liquid form that is contained within a flavor-coated, plastic sachet. Under optimal
conditions, when the sachet is pierced by an animal bite the vaccine is released into the buccal cavity
and coats the mucosal lining of the mouth. There the inant virus expressing the rabies
glycoprotein attaches and enters host cells, triggering an immune se. Previous studies have
shown that an approximate dose of 107.7 / 1.5 mL of RABORAL V-RG® is necessary to
protect a majority of raccoons from challenge with a wild-type rabies strain (Grosenbaugh, DA et al.
2007). However, because the vaccine is delivered in a liquid form, it is often spilled or rejected by the
animal, there are concerns related to the amount of RABORAL V-RG® an animal actually ingests
(Grosenbaugh, DA et al., 2007; Jojola, SM et al. 2007).
There are at least two potential mechanisms to increase the effectiveness of orally
administered RABORAL V-RG®: increase the viscosity of the vaccine and/or include an adjuvant.
Adjuvants are compounds that, when combined with a vaccine antigen, increase the immune response
to the e antigen as compared to the response induced by the vaccine n alone. Among
strategies that promote antigen immunogenicity are those that render vaccine ns particulate,
those that polymerize or emulsify vaccine antigens, methods of encapsulating vaccine antigens, ways
of increasing host innate cytokine responses, and methods that target vaccine antigens to antigen
presenting cells (Nossal, 1999, In: Fundamental logy. Paul (Ed.), Lippincott-Raven Publishers,
elphia, Pa.; Vogel and Powell, 1995, In: Vaccine Design. The Subunit and Adjuvant ch.
Powell and Newman , Plenum Press, NY, NY. p. 141). e of the essential role adjuvants
play in improving the immunogenicity of vaccine antigens, the use of adjuvants in the ation of
vaccines has been virtually ubiquitous (Nossal, 1999, supra; Vogel and Powell, 1995, supra; see also
PCT publication WO 97/18837, the teachings of which are incorporated herein by reference).
Conventional adjuvants, well-known in the art, are diverse in nature. They may, for example,
consist of water-insoluble inorganic salts, mes, es or emulsions, i.e. Freund’s adjuvant.
Other adjuvants may be found in Vogel and Powell, 1995, mentioned supra. Although there is no
single ism of adjuvant action, an essential characteristic is their ability to significantly increase
40 the immune response to a vaccine antigen as compared to the response induced by the vaccine
n alone (Nossal, 1999, supra; Vogel and Powell, 1995, supra). In this regard, some adjuvants
are more ive at augmenting humoral immune responses; other adjuvants are more effective at
sing cell-mediated immune responses (Vogel and Powell, 1995, supra); and yet another group
of adjuvants increase both humoral and cell-mediated immune responses against vaccine antigens
(Vogel and Powell, 1995, supra). In sum, adjuvants generally appear to exert their effects in at least
one of five ways: 1) facilitate n uptake, transport and presentation in the lymph nodes, 2) prolong
antigen presentation, 3) signal pathogen-recognition receptors (PRRs) expressed on innate immune
cells, 4) cause damage or stress to cells, which signals an immune response, and 5) induce a
ential Th1 or Th2 response (Schijns VE et al. 2007).
Some adjuvants have demonstrated particular adjuvanting utility, in part, by promoting
improved absorption through mucosal linings. Some examples include MPL, LTK63, toxins, PLG
microparticles and several others (Vajdy, M. Immunology and Cell y (2004) 82, 617–627), but
many of these are not practical to employ as part of a fe vaccination strategy due to the high
expense and/or poor stability in the field. One ably affordable mucosal adjuvant, chitosan (Van
der Lubben et al. 2001; Patel et al. 2005; Majithiya et al. 2008; US Patent Serial No. 5,980.912), has
demonstrated some efficacy when used in certain human vaccines, but the polymer has not previously
been successfully combined with veterinary biologics. Persons skilled in the vaccine development arts
understand that ive adjuvant/antigen/host combinations are ictable and require significant
experimentation to . See for e Edelman, “An Update on Vaccine Adjuvants in Clinical
Trial,” Aids Research and Human Retroviruses 409-1411 ; McElrath, “Selection of potent
immunological adjuvants for vaccine construction,” seminars in Cancer Biology 6:375-385 (1995);
Aucouturier et al., “Adjuvants designed for veterinary and human vaccines,” Vaccine 19:2666-2672
(2001); East et al., “Adjuvants for New Veterinary Vaccines,” Chapter 1 in Progress in Vaccinology,
vol. 4 Veterinary Vaccines, Springer Verlag, NY 1993, pp1-28; Altman et al., “Immunomodifiers in
Vaccines,” Advances In Veterinary Science and Comparative Medicine 33:301-343 (1989); and
Willson et al., “Tissue Reaction and ty in Swine Immunized with Actinobacillus
pneumoniae Vaccines,” Can J Vet Res 59:299-305 (1995).
In view of the current suboptimal vaccination of wildlife against ens such as rabies,
there is real and long-felt need for an nted vaccine bait that can be widely distributed at reduced
cost and increased efficacy. An ideal adjuvanted bait should 1) be safe, inexpensive and easy to
formulate, 2) reduce the amount of antigen dose required to e effective protection, 3) be
relatively more viscous, to reduce loss/spillage, and 4) be stable in the environment long enough for
the animals to become effectively vaccinated.
SUMMARY OF THE INVENTION
The ion is based, in part, on the unexpected and surprising result that RABORAL VRG
® formulated with specific variants of chitosan is effective for the oral vaccination of fe,
including ns. The invention further contemplates other formulations comprising antigens and
ans, wherein the chitosans provide improved vaccine efficacy by acting as vaccine adjuvants,
including increasing the viscosity of oral vaccine formulations, thereby promoting improved mucosal
40 absorption and/or transport.
In one embodiment, is provided a single-dose adjuvanted Rabies virus vaccine composition
comprising an attenuated recombinant Orthopox or Avipox viral vector and a methylated chitosan
derivative adjuvant, wherein the vector is capable of expressing in an animal host one or more Rabies
virus immunogens, and wherein the presence of the adjuvant is associated with both increased
viscosity, and increased protective efficacy against subsequent mental or natural challenge with
a virulent Rabies virus, as compared to an ise equivalent composition wherein the adjuvant has
been omitted.
In an embodiment, the effective dose is significantly lower than that required in e of the
inventive adjuvanting chitosans. In another embodiment, at least one other antigen may be added to
? the ive formulations.
The ion relates also to a method for screening candidate adjuvants in vitro, to reduce the
testing of compounds that have deleterious effects on the antigens. In particular, the instant disclosure
provides in vitro methods to assess whether/to what extent candidate adjuvants exert virucidal ty
on the vector component of vaccines. In an embodiment, only adjuvants with no or little virucidal
? effects are advanced to more costly and time-consuming animal studies.
In an embodiment, candidate adjuvants are combined with vaccine vector component and
allowed to incubate on cultured cells, ing but not solely, Vero, CEF, or any cell suitable or
ely employed for measuring the effective titer of recombinant viral vectors.
The ion further relates to a method of eliciting an immune response in a man
animal comprising administering the composition of any one of the preceding claims in an amount
effective for eliciting an immune response in the animal.
The invention r relates to a method of eliciting an immune response in a wild animal,
including raccoons and other wildlife, which may comprise administering a composition which may
comprise a viral vector which may comprise a rabies surface glycoprotein gene inserted into the viral
? vector genome in an amount effective for eliciting an immune se in the raccoon or other wildlife.
The method may include using compositions comprising an tives.
In a first embodiment the present invention provides for a novel adjuvanted rabies vaccine, or
vaccine bait for use in the wild, including, but not limited to, s, wetlands, and plains.
In one embodiment, the vector may comprise a modified live vaccinia virus. In another
embodiment, the rabies surface glycoprotein gene may be rabies glycoprotein G, which is derived from
an ERA strain in one ment.
In another ment, the vaccinia virus or the vaccinia virus vector may be a Copenhagen
strain or a derivative thereof. In another embodiment, the vaccinia virus or the vaccinia virus vector
may have a tk— phenotype. In an advantageous embodiment, the vaccinia virus or the vaccinia virus
? vector may be a Copenhagen strain (or a tive thereof) and has a tk— phenotype.
In an advantageous embodiment, the modified live vaccinia virus may be RABORAL V-RG®.
In another ment, administration of the above-described compositions may be oral and
be accomplished via a bait drop. In one embodiment, the bait drop may comprise a hollow plastic
packet. In another embodiment, the composition may be inserted in the hollow polymer cube. The bait
40? drop may also comprise a coated sachet.
In an embodiment, the coated sachet may be as described in Linhart et al., Journal of Wildlife
es, 2002, where RABORAL V-RG® was delivered using different baits with varying geometrical
shape and flavor (.
In yet another ment, the composition may be provided as described in US patent
number US 5,747,063. The vaccine may take the form indicated in FIGs. 2A-2C, wherein it comprises
an envelope (1), which comprises in admixture one or more craved for materials and one or more
substances agglomerating the craved for materials, the envelope possessing a high ical and
thermal resistance and being previously formed into a hollow shape riate for consumption by
the animal and defining an internal volume. such internal volume being filled by a craved for binder (3)
and comprising the active principle (2). the binder closely conforming the internal shape of the
envelope (1) in order to provide a continuity between the envelope (1) and the active ple (2), and
further comprising the instantly disclosed adjuvants.
In another ment, the ation efficacy achieved using RABOARL V-RG formulated
with an adjuvant according to the disclosure is significantly increased relative to vaccination efficacy
achieved using RABORAL V-RG® formulated t the adjuvant.
In yet another embodiment, administration of the above-described compositions may be nasal
or through contact with the nasal mucosa.
The ion also encompasses a method for inducing an immunological or tive
immune response in wildlife, including but not solely, raccoon, coyote, fox, skunk or mongoose, which
may comprise administering a composition which may comprise a viral vector which may comprise a
rabies surface glycoprotein gene inserted into the viral vector genome in an amount ive for
eliciting an immune response in the wild animal.
In one embodiment, the vector may comprise a modified live vaccinia virus. In another
embodiment, the rabies surface glycoprotein gene may be rabies glycoprotein G, which is derived from
an ERA strain in one embodiment.
In another embodiment, the vaccinia virus or the vaccinia virus vector may be a agen
strain or a derivative thereof. In another embodiment, the vaccinia virus or the vaccinia virus vector
may have a tk− phenotype. In an advantageous embodiment, the vaccinia virus or the vaccinia virus
vector may be a Copenhagen strain (or a derivative thereof) and has a tk− phenotype.
In an embodiment, the modified live vaccinia virus may be RABORAL V-RG® formulated with
trimethylated an.
The method also provides the use of the composition ing to the present disclosure in
the manufacture of a medicament for eliciting an immune response in an animal.
The invention also provides for a kit for performing any of the above bed methods
comprising the any of the above described compositions and optionally, instructions for performing the
method.
Another embodiment of the t invention provides for a stable, safe and easily
administrable vaccine. In an embodiment, the vaccine is a wildlife bait that is consumed by animals
including, but not solely, raccoons, s, foxes, rabbits, bats, squirrels, canines, and felines.
These and other embodiments are disclosed or are obvious from and encompassed by, the
following Detailed Description.
BRIEF DESCRIPTION OF DRAWINGS
A full and enabling disclosure of the present invention, including the best mode thereof, to one
of ordinary skill in the art, is set forth more particularly in the remainder of the specification, including
reference to the accompanying figures, wherein:
provides representative images of a fish meal polymer bait on left (2.0 X 3.5 X 3.5 cm,
26 g); a sachet bait in center (0.5 X 2.0 X 6.0 cm, ~3.8 g); and right, a typical sachet that has been
chewed, emptied of vaccine, and discarded by a raccoon;
represents a transversal section of a vaccine bait drop;
represents a longitudinal cross-section along line II-II of ;
represents a udinal cross-section along line III-III of ;
provides graph of average rabies virus neutralizing antibodies (IU/mL) over the course
of the study, with error bars identifying standard deviation.
DETAILED DESCRIPTION OF THE INVENTION
Other objects, features and aspects of the present invention are disclosed in, or are obvious
from, the following Detailed Description. It is to be tood by one of ordinary skill in the art that the
present discussion is a description of exemplary embodiments only and is not intended as limiting the
broader aspects of the t invention, which broader aspects are embodied in the exemplary
construction. In fact, it will be apparent to those skilled in the art that various modifications and
variations can be made in the present invention without departing from the scope or spirit of the
invention. For instance, features illustrated or described as part of one embodiment can be used in
another ment to yield a still further embodiment. It is intended that the present invention cover
such modifications and variations as come within the scope of the appended claims and their
equivalents. The contents of all references, published s, and patents cited hout the
t application are hereby incorporated by reference in their entirety.
Any discussion of nts, acts, materials, devices, articles or the like which has been
included in the present specification is not to be taken as an admission that any or all of these matters
form part of the prior art base or were common general knowledge in the field relevant to the present
disclosure as it existed before the priority date of each claim of this application.
For convenience, certain terms employed in the ication, Examples, and appended
Claims are collected here.
Unless otherwise explained, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this disclosure s.
The singular terms “a”, “an”, and “the” include plural referents unless context clearly tes
ise. Similarly, the word “or” is intended to e “and” unless the context clearly indicate
otherwise.
It is also noted that in this disclosure and ularly in the claims, terms such as “comprises”,
ised”, “comprising” and the like mean “includes”, “included”, “including”, and the like; and that
40 terms such as
sting essentially of” and “consists essentially of” allow for elements not explicitly recited, but
exclude elements that are found in the prior art or that affect a basic or novel characteristic of the
invention.
As used herein, the term “animal” includes all vertebrate animals including humans. Animal or
host includes mammals and human. The animal may be selected from the group consisting of equine
(e.g., horse), canine (e.g., dogs, wolves, foxes, coyotes, jackals), feline (e.g., lions, tigers, ic
cats, wild cats, other big cats, and other felines including cheetahs and lynx), ovine (e.g., sheep),
bovine (e.g., cattle), porcine (e.g., pig), caprine (e.g., goat), avian (e.g., chicken, duck, goose, turkey,
quail, pheasant, parrot, finches, hawk, crow, ostrich, emu and cassowary), primate (e.g., prosimian,
tarsier, monkey, gibbon, ape), and fish. The term “animal” also includes an individual animal in all
stages of pment, including embryonic and fetal .
As used herein, the term “virulent” means an isolate that retains its ability to be infectious in an
animal host.
As used herein, the term “inactivated vaccine” means a e composition containing an
ious sm or pathogen that is no longer capable of replication or growth. The pathogen may
be bacterial, viral, protozoal or fungal in origin. Inactivation may be accomplished by a variety of
s including freeze-thawing, chemical treatment (for example, treatment with formalin),
sonication, radiation, heat or any other convention means sufficient to prevent replication or growth of
the organism while maintaining its immunogenicity.
As used herein, the term “immunogenicity” means capable of producing an immune response
in a host animal against an antigen or antigens. This immune response forms the basis of the
protective immunity ed by a vaccine against a specific infectious organism.
As used herein, the term “immune response” refers to a se elicited in an animal. An
immune response may refer to cellular immunity (CMI); humoral immunity or may involve both. The
present invention also plates a response limited to a part of the immune system. For example,
a vaccine composition of the present invention may specifically induce an sed gamma interferon
response.
As used herein, the term “antigen” or “immunogen” means a substance that induces a specific
immune response in a host animal. The antigen may comprise a whole sm, killed, attenuated or
live; a subunit or portion of an organism; a recombinant vector ning an insert with immunogenic
properties; a piece or fragment of DNA e of inducing an immune response upon presentation to
a host animal; a protein, a polypeptide, a peptide, an epitope, a hapten, or any combination thereof.
Alternately, the immunogen or antigen may comprise a toxin or antitoxin.
As used herein, the term “multivalent” means a vaccine containing more than one antigen
whether from the same species (i.e., different isolates of Rabies virus serotypes), from a different
species (i.e., isolates from both Pasteurella hemolytica and Pasteurella multocida), or a vaccine
containing a combination of antigens from different genera (for example, a vaccine comprising
antigens from Pasteurella multocida, Salmonella, Escherichia coli, Haemophilus somnus and
Clostridium).
As used herein, the term ant” means a nce added to a vaccine to increase a
e’s immunogenicity, as compared with its efficacy in absence of the adjuvant. The mechanism of
how adjuvants e is not entirely known. Some adjuvants are believed to enhance the immune
se by slowly ing the n, while other adjuvants are ly immunogenic in their own
right and are believed to function synergistically. Known e adjuvants e, but are not limited
to, oil and water emulsions (for example, complete Freund's adjuvant and incomplete Freund's
adjuvant, and adjuvants disclosed in US patent numbers U87371395 to Merial Limited, which are
herein incorporated by reference in their entirety), Corynebacterium parvum, us Calmette Guerin,
aluminum hydroxide, glucan, dextran sulfate, iron oxide, sodium alginate, Bacto-Adjuvant, certain
synthetic polymers such as poly amino acids and co-polymers of amino acids, saponin, "REGRESSIN"
(Vetrepharm, Athens, Ga.), "AVRIDINE" (N, tadecyl-N',N'-bis(2-hydroxyethyl)—propanediamine),
paraffin oil, muramyl dipeptide and the like.
As used , the term “emulsion” refers to a combination of at least two substances,
wherein a first substance is dispersed in a second substance in which the first substance is insoluble.
One example of an emulsion of the present invention is an oil phase dispersed in an aqueous phase.
As used herein, the terms “pharmaceutically acceptable carrier” and “pharmaceutically
4o acceptable vehicle” are interchangeable and refer to a fluid vehicle for containing vaccine antigens that
can be injected into a host without adverse effects. Suitable pharmaceutically acceptable carriers
known in the art include, but are not limited to, sterile water, saline, glucose, dextrose, or buffered
solutions. Carriers may include auxiliary agents including, but not limited to, diluents, stabilizers (i.e.,
sugars and amino acids), preservatives, g agents, emulsifying agents, pH buffering agents,
viscosity enhancing additives, colors and the like.
As used herein, the term “vaccine composition” includes at least one antigen or gen in
a pharmaceutically acceptable vehicle useful for inducing an immune response in a host. Vaccine
compositions can be stered in dosages and by techniques well known to those skilled in the
medical or veterinary arts, taking into consideration such factors as the age, sex, weight, species and
condition of the recipient animal, and the route of administration. The route of administration can be
percutaneous, via mucosal administration (e.g., oral, nasal, anal, vaginal) or via a parenteral route
(intradermal, uscular, subcutaneous, intravenous, or intraperitoneal). Vaccine itions can
be administered alone, or can be co-administered or sequentially administered with other treatments
or therapies. Forms of administration may include suspensions, syrups or s, and preparations for
parenteral, aneous, intradermal, intramuscular or intravenous stration (e.g., injectable
administration) such as sterile suspensions or emulsions. Vaccine compositions may be administered
as a spray or mixed in food and/or water or delivered in admixture with a suitable r, diluent, or
excipient such as sterile water, physiological saline, glucose, or the like. The compositions can contain
auxiliary substances such as wetting or emulsifying agents, pH buffering agents, adjuvants, gelling or
ity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the
route of stration and the preparation desired. rd pharmaceutical texts, such as
gton's Pharmaceutical Sciences,” 1990 may be consulted to prepare suitable preparations,
without undue experimentation.
The term “purified” as used herein does not require absolute purity; rather, it is intended as a
relative term. Thus, for example, a purified gen preparation, such as protein or inactivated
virus, is one in which the immunogen is more ed than the immunogen is in its natural
environment. An immunogen preparation is herein broadly referred to as “purified” such that the
immunogen represents at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least
98%, of the total immunogen content of the preparation. A “crude preparation”, which represents the
lowest degree of purification, may contain as little as less than 60%, lest than 20%, less than 10%,
less than 5%, or less than 1% of immunogenic components.
The term “highly purified” as used herein is intended to suggest a r degree of purity” as
compared to the term “moderately purified”. This “higher degree of purity” can include, but is in no way
limited to, reduced percentages of contaminants, in an immunological preparation that has been
“highly purified" versus an immunological preparation that has been ately ed”. As
discussed herein, “highly purified” immunological ations will have the lowest to undetectable
percentages of contaminants that can cause: reduced desired immune se, increased undesired
immune response (e.g. ensitivity reaction), or reduced formulation stability. Similarly, an
immunological preparation that has been “moderately purified” contains relatively reduced percentages
40 of contaminants versus an logical preparation that has been “minimally purified”, which
likewise, has reduced percentages of contaminants versus a ation designated a “crude
preparation”.
Contaminants in an immunological preparation can include, but are in no way limited to,
substances that contribute negatively to an immunological composition according to the present
invention. One of l examples of a contaminant contributing negatively would be a contaminant
that reduces the ability of an immunological composition of the present invention to elicit an immune
response in animals.
Varying levels of purity (e.g. “highly purified”, “moderately purified”, and the like) can be
achieved using various methods. For example, a combination of chromatography and size exclusion
gel filtration can result in a “highly purified” or "moderately purified" immunological preparations.
Differences in source/type of immunogens, as well as slight variations in purification procedures can
icantly affect the final degree of immunogen purity. In general, as used herein, immunological
preparations having the lowest to highest percentage of contaminants will be described as 1) “highly
ed, 2) “moderately purified”, 3) “minimally purified”, 4) “crude preparation”, respectively. A “highly
purified” preparation will have the lowest level across all types of contaminants. A “moderately purified”
preparation will have relatively low levels of most types of contaminants, but may have one type of
contaminant in higher abundance than would be ed for a comparable y purified”
preparation. Likewise, a ally purified preparation” will have relatively low levels of some types of
contaminants, but may have more than one type of contaminant in higher abundance than a
comparable “moderately purified” preparation. As expected, a “crude ation” has the highest level
of contaminants, across all inant types, as compared to the other types of preparations
discussed herein.
In another embodiment, the rabies glycoprotein is any rabies glycoprotein with a known
n sequence, such as rabies virus glycoprotein G. such as the n sequences in or derived
from the nucleotide sequences in Marissen et al., J Virol. April 2005;79(8):4672—8; Dietzschold et al.,
Vaccine. December 9, 2004;23(4):518—24; Mansfield et al., J Gen Virol. November 2004;85(Pt
11):3279-83; Sato et al., J Vet Med Sci. July 2004;66(7):747-53; Takayama-lto et al., J Neurovirol.
April 2004;10(2):131-5; Li et al., Zhongguo Yi Xue Ke Xue Yuan Xue Bao. December 5(6):650-
4; Hemachudha et al., J Infect Dis. Oct. 1, 2003;188(7):960-6; amge et al., Microbiol lmmunol.
2003;47(7):507—19; Maillard et al., Virus Res. June 2003;93(2):151-8; lrie et al. Microbiol lmmunol.
2002;46(7):449—61; Langevin et al., J Biol Chem. Oct. 4, 2002;277(40):37655-62; Maillard and Gaudin,
J Gen Virol. June 2002;83(Pt 6):1465-76; Holmes et al., Virology. Jan. 20, 2002;292(2):247-57;
Mebatsion, J Virol. er 2001;75(23):11496-502; Zhang et al., Zhonghua Shi Yan He Lin
Chuang Bing Du Xue Za Zhi. September 2000;14(3):281-4; Ray et al., Clin Exp lmmunol. July
2001;125(1):94—101; Morimoto et al., Vaccine. May 14, 2001;19(25-26):3543-51; Morimoto et al., J
Neurovirol. October (5):373-81; Bourhy et al., J Gen Virol. October 1999;80 (Pt 10):2545-57;
Kissi et al., J Gen Virol. August 1999;80 (Pt 8):2041-50; Nakahara et al., Microbiol lmmunol.
1999;43(3):259—70; Matthews et al., J Gen Virol. February 1999;80 (Pt 2):345—53; Tuffereau et al.,
EMBO J. Dec. 15, 1998;17(24):7250-9; Jallet et al. J Virol. January 1999;73(1):225—33; Wloch et al.,
4o Hum Gene Ther. Jul. 1, 1998;9(10):1439-47; ist et al., Biochemistry. May 12, 1998;37(19):6833-
7; to et al., Proc Natl Acad Sci U S A. Mar. 17, 5(6):3152-6; Coll, Arch Virol.
1997;142(10):2089-97; Bracci et al., Blood. Nov. 1, 1997;90(9):3623-8; Gaudin et al., J Virol.
er 1996;70(11):7371-8; Morimoto et al., Proc Natl Acad Sci U S A. May 28, 1996;93(11):5653-
8; Mebatsion et al., Cell. Mar. 22, 1996;84(6):941-51; Shakin-Eshleman et al., J Biol Chem. Mar. 15,
1996;271(11):6363-6; Nadin-Davis et al., J Virol Methods. March 1996;57(1):1-14. Erratum in: J Virol
Methods Apr. 26, 8(1-2):209; Wojczyk et al., Protein Exp. Purif. March 1996;7(2):183-93;
Suzuki et al., J Gen Virol. December 1995;76 (Pt 12):3021-9; Raux et al., Virology. Jul. 10,
1995;210(2):400-8; Kasturi et al., J Biol Chem. Jun. 16, 1995;270(24):14756-61; Otvos et al., Biochim
Biophys Acta. May 29, 1995;1267(1):55-64; Mebatsion et al., J Virol. March 1995;69(3):1444-51;
Wojczyk B, Shakin-Eshleman S H, Doms R W, Xiang Z Q, Ertl H C, Wunner W H, Spitalnik,
Biochemistry. Feb. 28, 1995;34(8):2599-609; Ravkov et al., Virology. Jan. 10, 1995;206(1):718—23; Ni
et al., Microbiol Immunol. 1995;39(9):693-702; Coll, Arch Virol. 1995;140(5):827-51; Grabko et al.,
Dokl Akad Nauk. July 1994;337(1):117-21; Sakamoto et al., Virus Genes. January 1994;8(1):35—46;
Fodor et al., Arch Virol. 1994;135(3-4):451-9; Ito et al., Microbiol l. 1994;38(6):479-82; Shakin-
Eshleman et al., Biochemistry. Sep. 14, 2(36):9465-72; Morimoto et al., Virology. August
1993;195(2):541-9; van der n et al., J Gen Virol. August 1993;74 (Pt 8):1539-45; Nishihara et
al., Gene. Jul. 30, 1993;129(2):207-14; i et al., Biopolymers. June 1993;33(6):961-9; McColl et
al., Aust Vet J. March 1993;70(3):84-9; Bai et al., Virus Res. February 1993;27(2):101—12; Nishihara et
al., Nippon Rinsho. February 1993;51(2):323-8; Bracci et al., FEBS Lett. Oct. 19, 1992;311(2):115-8;
Tuchiya et al., Virus Res. Sep. 1, 1992;25(1-2):1-13; Shakin-Eshleman et al., J Biol Chem. May 25,
1992;267(15):10690-8; Whitt et al., Virology. December 1991 ;185(2):681-8; Benmansour et al., J Virol.
August 1991;65(8):4198—203; Burger et al., J Gen Virol. February 1991;72 (Pt 2):359—67; Dietzschold
et al., J Virol. August 1990;64(8):3804-9; , Virus Genes. ry (3):277—84; d et
al., Virology. December 1989;173(2):390-9 and Wang et al., Chin Med J (Engl). November
1989;102(11):885-9, the disclosures of which are incorporated by reference in their entireties, may be
used in the present ion.
A “polynucleotide” is a polymeric form of nucleotides of any length, which contain
deoxyribonucleotides, ribonucleotides, and analogs in any ation. cleotides may have
three-dimensional structure, and may perform any function, known or unknown. The term
“polynucleotide” includes double-, single-stranded, and triple-helical molecules. Unless othenNise
specified or required, any embodiment of the invention described herein that is a polynucleotide
encompasses both the double stranded form and each of two complementary forms known or
predicted to make up the double stranded form of either the DNA, RNA or hybrid molecule.
The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons,
introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched
polynucleotides, plasmids, vectors, isolated DNA of any ce, isolated RNA of any sequence,
nucleic acid probes and primers. A polynucleotide may comprise modified nucleotides, such as
methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as
fluororibose and thiolate, and nucleotide branches. The sequence of tides may be further
4o modified after polymerization, such as by conjugation, with a labeling component. Other types of
modifications included in this definition are caps, substitution of one or more of the naturally occurring
nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins,
metal ions, labeling components, other polynucleotides or solid support.
An “isolated" cleotide or polypeptide is one that is substantially free of the materials with
which it is associated in its native environment. By substantially free, is meant at least 50%,
ageously at least 70%, more ageously at least 80%, and even more advantageously at
least 90% free of these materials.
The invention r comprises a complementary strand to a rabies glycoprotein
polynucleotide.
The complementary strand can be polymeric and of any length, and can contain
deoxyribonucleotides, ribonucleotides, and analogs in any ation.
Hybridization reactions can be performed under ions of different “stringency.” Conditions
that increase stringency of a hybridization on are well known. See for examples, “Molecular
Cloning: A Laboratory Manual”, second edition (Sambrook et al. 1989). Examples of relevant
ions include (in order of increasing stringency): tion temperatures of 25° C., 37° C., 50°
C., and 68° C.; buffer concentrations of 10><SSC, 6XSSC, 1><SSC, 0.1><SSC (where SSC is 0.15 M
NaCl and 15 mM citrate ) and their equivalent using other buffer systems; formamide
concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1, 2 or more
washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6XSSC, 1><SSC,
0.1 XSSC, or deionized water.
The invention further encompasses polynucleotides encoding functionally equivalent ts
and derivatives of a rabies glycoprotein polypeptides and functionally equivalent fragments thereof
which may enhance, decrease or not significantly affect properties of the polypeptides encoded
thereby. These functionally equivalent variants, derivatives, and fragments display the ability to retain
rabies glycoprotein activity. For instance, changes in a DNA sequence that do not change the encoded
amino acid sequence, as well as those that result in conservative substitutions of amino acid residues,
one or a few amino acid deletions or additions, and substitution of amino acid residues by amino acid
s are those which will not significantly affect properties of the encoded polypeptide.
Conservative amino acid substitutions are glycine/alanine; valine/isoleucine/leucine;
asparagine/glutamine; aspartic acid / ic acid; serine/threonine/methionine; lysine/arginine; and
phenylalanine / tyrosine / tryptophan.
For the purposes of the present invention, ce identity or homology is determined by
comparing the sequences when aligned so as to maximize overlap and identity while minimizing
sequence gaps. In particular, sequence identity may be determined using any of a number of
atical algorithms. A nonlimiting example of a mathematical algorithm used for comparison of
two sequences is the algorithm of Karlin & Altschul, Proc. Natl. Acad. Sci. USA 7: 2264-2268,
modified as in Karlin & Altschul, Proc. Natl. Acad. Sci. USA 1993;90: 5873-5877.
r example of a atical algorithm used for comparison of ces is the
algorithm of Myers & Miller, CABIOS 1988;4: 11-17. Such an algorithm is incorporated into the ALIGN
4o program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing
the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap
length penalty of 12, and a gap penalty of 4 can be used. Yet another useful algorithm for identifying
regions of local sequence rity and alignment is the FASTA algorithm as described in Pearson &
Lipman, Proc. Natl. Acad. Sci. USA 1988;85: 2444-2448.
ageous for use according to the present invention is the WU-BLAST (Washington
University BLAST) version 2.0 software. WU-BLAST version 2.0 executable programs for several
UNIX platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. This program is based
on ST version 1.4, which in turn is based on the public domain NCBl-BLAST version 1.4
(Altschul & Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266: 460-480;
ul et al., Journal of Molecular Biology 1990;215: 403-410; Gish & , ature Genetics
3: 266-272; Karlin & Altschul, 1993;Proc. Natl. Acad. Sci. USA 90: 5873-5877; all of which are
incorporated by reference herein).
In general, comparison of amino acid sequences is accomplished by aligning an amino acid
sequence of a polypeptide of a known structure with the amino acid sequence of a the polypeptide of
unknown structure. Amino acids in the sequences are then compared and groups of amino acids that
are homologous are grouped together. This method detects ved regions of the polypeptides and
ts for amino acid insertions and deletions. Homology between amino acid sequences can be
determined by using commercially available algorithms (see also the description of homology above).
In addition to those othenNise mentioned herein, mention is made too of the programs BLAST, gapped
BLAST, BLASTN, , and PSI-BLAST, provided by the National Center for hnology
Information. These programs are widely used in the art for this e and can align homologous
regions of two amino acid sequences.
In all search programs in the suite the gapped alignment routines are integral to the database
search itself. Gapping can be turned off if desired. The default y (Q) for a gap of length one is
Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer. The default
per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN,
but may be changed to any integer. Any ation of values for Q and R can be used in order to
align sequences so as to maximize overlap and ty while minimizing sequence gaps. The default
amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM
can be utilized.
Alternatively or additionally, the term “homology” or “identity”, for instance, with respect to a
nucleotide or amino acid sequence, can indicate a quantitative measure of homology between two
sequences. The percent sequence gy can be calculated as (Nref—Ndif)*100/Nref, wherein Ndif
is the total number of entical residues in the two sequences when aligned and wherein Nref is
the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a
sequence identity of 75% with the sequence TC (Nref=8; Ndif=2).
Alternatively or additionally, ogy” or “identity” with respect to sequences can refer to the
number of ons with identical nucleotides or amino acids divided by the number of nucleotides or
amino acids in the shorter of the two sequences wherein alignment of the two sequences can be
40 determined in accordance with the Wilbur and Lipman algorithm (Wilbur & Lipman, Proc Natl Acad Sci
USA 1983;80:726, incorporated herein by reference), for instance, using a window size of 20
nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and er-assisted is
and interpretation of the sequence data including alignment can be iently performed using
commercially available programs (e.g., igeneticsTM Suite, lntelligenetics Inc. CA). When RNA
sequences are said to be similar, or have a degree of sequence identity or homology with DNA
sequences, ine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence.
Thus, RNA sequences are within the scope of the invention and can be derived from DNA sequences,
by thymidine (T) in the DNA sequence being-considered equal to uracil (U) in RNA ces.
And, t undue mentation, the skilled artisan can consult with many other programs
or references for determining percent homology.
The invention r encompasses a rabies glycoprotein contained in a vector molecule or an
expression vector and operably linked to an enhancer and/or a promoter element if necessary. In an
advantageous embodiment, the promoter is a cytomegalovirus (CMV) er. In r
embodiment, the enhancers and/or promoters include various cell or tissue specific promoters, s
viral promoters and enhancers and various rabies glycoprotein DNA sequences isogenically specific
for each animal species.
A “vector” refers to a recombinant DNA or RNA plasmid or virus that comprises a heterologous
polynucleotide to be delivered to a target cell, either in vitro or in vivo. The heterologous polynucleotide
may comprise a sequence of interest for purposes of therapy, and may optionally be in the form of an
expression cassette. As used herein, a vector need not be capable of replication in the ultimate target
cell or subject. The term includes cloning vectors for translation of a polynucleotide encoding
sequence. Also included are viral vectors.
The term “recombinant” means a polynucleotide of genomic cDNA, semisynthetic, or synthetic
origin which either does not occur in nature or is linked to another polynucleotide in an arrangement
not found in nature.
“Heterologous” means derived from a genetically distinct entity from the rest of the entity to
which it is being ed. For example, a polynucleotide, may be placed by genetic engineering
techniques into a plasmid or vector derived from a different source, and is a heterologous
polynucleotide. A promoter removed from its native coding sequence and operatively linked to a
coding sequence other than the native sequence is a heterologous er.
The polynucleotides of the invention may comprise additional sequences, such as additional
encoding sequences within the same transcription unit, controlling ts such as promoters,
ribosome binding sites, polyadenylation sites, additional transcription units under control of the same
or a different er, sequences that permit cloning, expression, homologous recombination, and
ormation of a host cell, and any such construct as may be desirable to provide embodiments of
this invention.
Elements for the expression of rabies glycoprotein are advantageously t in an inventive
vector. In minimum manner, this comprises, consists essentially of, or consists of an initiation codon
(ATG), a stop codon and a promoter, and optionally also a polyadenylation sequence for certain
40 vectors such as plasmid and certain viral s, e.g., viral vectors other than poxviruses. When the
polynucleotide encodes a polyprotein fragment, e.g. rabies glycoprotein, advantageously, in the vector,
an ATG is placed at 5' of the reading frame and a stop codon is placed at 3'. Other elements for
controlling expression may be present, such as enhancer sequences, izing sequences and signal
sequences permitting the ion of the protein.
Methods for making and/or administering a vector or recombinants or d for sion
of gene ts of genes of the invention either in vivo or in vitro can be any desired method, e.g., a
method which is by or analogous to the methods disclosed in, or disclosed in documents cited in: US.
Pat. Nos. 4,603,112; 4,769,330; 4,394,448; 4,722,848; 4,745,051; 4,769,331; 4,945,050; 5,494,807;
,514,375; 140; 5,744,141; 5,756,103; 5,762,938; 5,766,599; 5,990,091; 5,174,993; 5,505,941;
5,338,683; 5,494,807; 5,591,639; 5,589,466; 5,677,178; 5,591,439; 5,552,143; 5,580,859; 6,130,066;
777; 6,130,066; 6,497,883; 6,464,984; 6,451,770; 6,391,314; 6,387,376; 6,376,473; 6,368,603;
6,348,196; 400; 6,228,846; 6,221,362; 6,217,883; 6,207,166; 6,207,165; 6,159,477; 6,153,199;
6,090,393; 6,074,649; 6,045,803; 6,033,670; 6,485,729; 6,103,526; 6,224,882; 682; 6,348,450
and 683; US. patent application Ser. No. 920,197, filed Oct. 16,1986; WO 90/01543;
WO91/11525; WO 94/16716; WO 96/39491; WO 98/33510; EP 265785; EP 0 370 573; Andreansky et
al., Proc. Natl. Acad. Sci. USA 1996;93:11313-11318; Ballay et aI., EMBO J. 1993;423861-65; Felgner
et al., J. Biol. Chem. 69:2550-2561; Frolov et al., Proc. Natl. Acad. Sci. USA 1996;93:11371-
11377; Graham, Tibtech 1990;8:85-87; Grunhaus et aI., Sem. Virol. 1992;3:237—52; Ju et aI.,
Diabetologia 1998;41:736-739; Kitson et al., J. Virol. 1991;65:3068-3075; McClements et al., Proc.
Natl. Acad. Sci. USA 1996;93:11414-11420; Moss, Proc. Natl. Acad. Sci. USA 1996;93:11341-11348;
Paoletti, Proc. Natl. Acad. Sci. USA 1996;93:11349-11353; Pennock et aI., Mol. Cell. Biol. 1984;4:399-
406; Richardson (Ed), Methods in Molecular Biology 1995;39, “Baculovirus Expression Protocols,”
Humana Press Inc; Smith et al. (1983) Mol. Cell. Biol. 1983;3:2156-2165; Robertson et al., Proc. Natl.
Acad. Sci. USA 1996;93:11334-11340; Robinson et aI., Sem. lmmunol. 1997;9:271; and Roizman,
Proc. Natl. Acad. Sci. USA 1996;93:11307-11312. Thus, the vector in the ion can be any
suitable recombinant virus or virus vector, such as a poxvirus (e.g., vaccinia virus, avipox virus,
canarypox virus, fowlpox virus, raccoonpox virus, swinepox virus, etc.), adenovirus (e.g., canine
adenovirus), herpesvirus, baculovirus, retrovirus, etc. (as in nts incorporated herein by
reference); or the vector can be a plasmid. The herein cited and incorporated herein by reference
documents, in addition to providing es of vectors useful in the practice of the invention, can also
provide sources for non- rabies glycoprotein proteins or fragments thereof, e.g., non-rabies
glycoprotein proteins or fragments thereof, cytokines, etc. to be expressed by vector or vectors in, or
included in, the compositions of the ion.
The present invention also relates to preparations comprising s, such as expression
vectors, e.g., therapeutic compositions. The preparations can comprise, t essentially of, or
consist of one or more vectors, e.g., expression s, such as in vivo expression vectors,
comprising, ting essentially or consisting of (and advantageously expressing) one or more of a
rabies glycoprotein polynucleotides and, advantageously, the vector contains and expresses a
polynucleotide that includes, consists essentially of, or consists of a coding region encoding rabies
4o glycoprotein, in a pharmaceutically or narily acceptable r, excipient or vehicle. Thus,
ing to an embodiment of the invention, the other vector or vectors in the preparation comprises,
ts ially of or consists of a polynucleotide that encodes, and under appropriate
circumstances the vector expresses one or more other proteins of rabies glycoprotein or a fragment
thereof.
According to another ment, the vector or vectors in the preparation comprise, or
t essentially of, or consist of po|ynuc|eotide(s) encoding one or more proteins or fragment(s)
thereof of rabies glycoprotein, the vector or vectors have express of the po|ynuc|eotide(s). The
inventive preparation advantageously comprises, consists essentially of, or consists of, at least two
vectors comprising, consisting essentially of, or consisting of, and advantageously also sing,
advantageously in vivo under appropriate conditions or le conditions or in a suitable host cell,
po|ynuc|eotides from different rabies rotein isolates encoding the same proteins and/or for
different ns, but advantageously for the same proteins. As to preparations containing one or
more vectors containing, ting essentially of or consisting of po|ynuc|eotides encoding, and
advantageously expressing, advantageously in vivo, rabies glycoprotein, or an epitope thereof, it is
advantageous that the expression products be from two, three or more different rabies glycoprotein
isolates, advantageously strains. The invention is also directed at mixtures of vectors that contain,
consist essentially of, or consist of coding for, and express, different rabies proteins.
In an embodiment, the vector is a viral vector, which may be a vaccinia virus vector ning
the rabies glycoprotein gene. The rabies glycoprotein may be rabies rotein G d from the
ERA strain. In an ageous ment, the vaccinia virus can be a Copenhagen strain and/or a
tk— phenotype. In a ularly ageous embodiment, the vector is a vaccinia virus vector
hagen strain and tk— phenotype) with the rabies virus glycoprotein G encoded therein,
advantageously RABORAL V-RG®.
In one particular embodiment the viral vector is a poxvirus, e.g. a vaccinia virus or an
attenuated vaccinia virus, (for instance, MVA, a modified Ankara strain obtained after more than 570
passages of the Ankara vaccine strain on chicken embryo fibroblasts; see Stickl & Hochstein-Mintzel,
Munch. Med. Wschr., 1971, 113, 1149-1153; Sutter et al., Proc. Natl. Acad. Sci. U.S.A., 1992, 89,
10847-10851; available as ATCC VR—1508; or NYVAC, see U.S. Pat. No. 5,494,807, for instance,
Examples 1 to 6 and et seq of U.S. Pat. No. 5,494,807 which discuss the construction of NYVAC, as
well as variations of NYVAC with additional ORFs deleted from the Copenhagen strain vaccinia virus
genome, as well as the insertion of heterologous coding nucleic acid molecules into sites of this
recombinant, and also, the use of matched promoters; see also WO96/40241), an avipox virus or an
attenuated avipox virus (e.g., canarypox, fowlpox, dovepox, pigeonpox, quailpox, ALVAC or TROVAC;
see, e.g., US. Pat. Nos. 5,505,941, 5,494,807), swinepox, npox, camelpox, or myxomatosis
virus.
According to another embodiment of the invention, the poxvirus vector is a canarypox virus or
a fowlpox virus vector, advantageously an attenuated canarypox virus or fowlpox virus. In this regard,
is made to the canarypox available from the ATCC under access number VR-111. Attenuated
canarypox viruses are described in US. Pat. No. 5,756,103 (ALVAC) and WOO1/05934. Numerous
40 fowlpox virus vaccination strains are also available, e.g. the DIFTOSEC CT strain marketed by
MERIAL and the NOBILIS VARIOLE vaccine marketed by INTERVET; and, reference is also made to
US. Pat. No. 599 which pertains to the attenuated fowlpox strain TROVAC.
For information on the method to generate recombinants f and how to administer
recombinants thereof, the skilled n can refer documents cited herein and to WO90/12882, e.g.,
as to vaccinia virus mention is made of US. Pat. Nos. 4,769,330, 4,722,848, 4,603,112, 5,110,587,
,494,807, and 938 inter alia; as to fowlpox, n is made of US. Pat. Nos. 5,174,993,
941 and US. Pat. No. 5,766,599 inter alia; as to canarypox mention is made of U.S. Pat. No.
,756,103 inter alia; as to swinepox n is made of US. Pat. No. 425 inter alia; and, as to
raccoonpox, mention is made of W000/03030 inter alia.
When the expression vector is a vaccinia virus, insertion site or sites for the polynucleotide or
polynucleotides to be expressed are advantageously at the thymidine kinase (TK) gene or insertion
site, the hemagglutinin (HA) gene or insertion site, the region encoding the inclusion body of the A type
(ATI); see also documents cited herein, especially those pertaining to vaccinia virus. In the case of
canarypox, advantageously the insertion site or sites are ORF(s) C3, C5 and/or C6; see also
documents cited herein, especially those pertaining to canarypox virus. In the case of fowlpox,
advantageously the insertion site or sites are ORFs F7 and/or F8; see also documents cited herein,
especially those pertaining to x virus. The insertion site or sites for MVA virus area
advantageously as in various publications, including Carroll M. W. et al., Vaccine, 1997, 15 (4), 387-
394; Stittelaar K. J. et al., J. Virol., 2000, 74 (9), 4236-4243; Sutter G. et al., 1994, Vaccine, 12 (11),
1032-1040; and, in this regard it is also noted that the complete MVA genome is described in Antoine
G., Virology, 1998, 244, 365-396, which enables the skilled artisan to use other insertion sites or other
promoters.
Advantageously, the polynucleotide to be expressed is inserted under the control of a specific
poxvirus promoter, e.g., the vaccinia promoter 7.5 kDa (Cochran et al., J. Virology, 1985, 54, 30-35),
the vaccinia promoter 13L (Riviere et al., J. Virology, 1992, 66, 3424-3434), the vaccinia promoter HA
(Shida, Virology, 1986, 150, 451-457), the cowpox er ATl (Funahashi et al., J. Gen. ,
1988, 69, 35-47), the vaccinia promoter H6 (Taylor J. et al., Vaccine, 1988, 6, 504-508; Guo P. et al. J.
, 1989, 63, 4189-4198; Perkus M. et al., J. Virol., 1989, 63, 3829-3836), inter alia.
Advantageously, for the vaccination of mammals the expression vector is a canarypox or a
fowlpox. In this way, there can be expression of the heterologous proteins with d or no productive
replication.
According to one ment of the invention, the expression vector is a viral vector, in
particular an in vivo expression vector. In an advantageous embodiment, the expression vector is an
irus vector, such as a human adenovirus (HAV) or a canine adenovirus (CAV).
Advantageously, the adenovirus is a human Ad5 vector, an E1-deleted and/or disrupted adenovirus,
an E3-deleted and/or disrupted adenovirus or an E1- and E3-deleted and/or disrupted adenovirus.
Optionally, E4 may be deleted and/or ted from any of the adenoviruses described above. For
e, the human Ad5 vectors expressing a rabies glycoprotein gene described in Yarosh et al. and
Lutze-Wallace et al. can be used in s of the invention (see, e.g., Yarosh et al., Vaccine.
4o September 1996;14(13):1257-64 and Lutze-Wallace et al., Biologicals. December 1995;23(4):271-7).
In one embodiment the viral vector is a human adenovirus, in particular a serotype 5
adenovirus, rendered etent for replication by a deletion in the E1 region of the viral genome.
The deleted adenovirus is propagated in E1-expressing 293 cells or PER cells, in particular PER.C6
(F. Falloux et al Human Gene Therapy 1998, 9, 917). The human adenovirus can be deleted in
the E3 region ally in combination with a deletion in the E1 region (see, e.g. J. Shriver et al.
Nature, 2002, 415, 331-335, F. Graham et al Methods in Molecular Biology Vol 7: Gene Transfer and
Expression Protocols Edited by E. Murray, The Human Press Inc, 1991, p 109-128; Y. Ilan et al Proc.
Natl. Acad. Sci. 1997, 94, 592; S. hy et al Proc. Natl. Acad. Sci. 1994, 91, 11557-11561;
B. Tapnell Adv. Drug Deliv. Rev.1993, 12, 185-199;X. Danthinne et al Gene Thrapy 2000, 7, 1707-
1714; K. Berkner Bio Techniques 1988, 6, 616-629; K. Berkner et al Nucl. Acid Res. 1983, 11, 6003-
6020; C. Chavier et al J. Virol. 1996, 70, 4805-4810). The insertion sites can be the E1 and/or E3 loci
eventually after a partial or complete on of the E1 and/or E3 regions. Advantageously, when the
sion vector is an adenovirus, the polynucleotide to be expressed is inserted under the control of
a promoter functional in eukaryotic cells, such as a strong promoter, preferably a cytomegalovirus
immediate-early gene promoter (CMV-IE promoter). The CMV-IE promoter is advantageously of
murine or human origin. The promoter of the elongation factor 1d can also be used. In one particular
embodiment a promoter regulated by hypoxia, e.g. the promoter HRE described in K. Boast et al
Human Gene Therapy 1999, 13, 2197-2208), can be used. A muscle specific promoter can also be
used (X. Li et al Nat. Biotechnol. 1999, 17, 241-245). Strong promoters are also discussed herein in
relation to plasmid vectors. A poly(A) sequence and terminator sequence can be inserted downstream
the polynucleotide to be expressed, e.g. a bovine growth e gene or a rabbit in gene
polyadenylation signal.
In another embodiment the viral vector is a canine adenovirus, in particular a CAV-2 (see, e.g.
L. Fischer et al. Vaccine, 2002, 20, 3485-3497; US. Pat. Nos. 5,529,780; 5,688,920; PCT Application
No. WO95/14102). For CAV, the insertion sites can be in the E3 region and/or in the region located
n the E4 region and the right ITR region (see US. Pat. Nos. 6,090,393; 6,156,567). In one
ment the insert is under the control of a promoter, such as a cytomegalovirus immediate-early
gene promoter (CMV-IE promoter) or a promoter already described for a human adenovirus vector. A
poly(A) sequence and terminator sequence can be inserted downstream the polynucleotide to be
expressed, e.g. a bovine growth hormone gene or a rabbit B-globin gene polyadenylation signal.
In another particular embodiment the viral vector is a herpesvirus such as a canine
herpesvirus (CHV) or a feline virus (FHV). For CHV, the insertion sites may be in particular in
the thymidine kinase gene, in the ORF3, or in the UL43 ORF (see US. Pat. No. 477). In one
embodiment the polynucleotide to be expressed is inserted under the control of a promoter functional
in eukaryotic cells, advantageously a CMV-IE promoter (murine or human). In one particular
embodiment a er ted by hypoxia, e.g. the promoter HRE described in K. Boast et al
Human Gene Therapy 1999, 13, 2197-2208), can be used. A poly(A) sequence and terminator
ce can be inserted ream the polynucleotide to be expressed, e.g. bovine growth
e or a rabbit B-globin gene polyadenylation signal.
According to a yet further embodiment of the invention, the sion vector is a plasmid
vector or a DNA plasmid vector, in particular an in vivo expression vector. In a specific, miting
example, the pVR1020 or 1012 plasmid (VICAL Inc.; Luke C. et al., Journal of Infectious es,
1997, 175, 91-97; Hartikka J. et al., Human Gene Therapy, 1996, 7, 1205-1217) can be utilized as a
vector for the insertion of a polynucleotide sequence. The pVR1020 plasmid is derived from pVR1012
and contains the human tPA signal sequence.
The term plasmid covers any DNA ription unit comprising a polynucleotide according to
the invention and the ts necessary for its in vivo expression in a cell or cells of the desired host
or target; and, in this regard, it is noted that a supercoiled or non-supercoiled, circular plasmid, as well
as a linear form, are intended to be within the scope of the invention.
Each d comprises or ns or consists essentially of, in addition to the polynucleotide
ng a rabies glycoprotein variant, analog or fragment, operably linked to a promoter or under the
control of a promoter or dependent upon a er. In general, it is advantageous to employ a strong
promoter functional in eukaryotic cells. The preferred strong promoter is the immediate early
galovirus promoter (CMV-IE) of human or murine origin, or optionally having another origin
such as the rat or guinea pig. The CMV-IE promoter can comprise the actual promoter part, which may
or may not be associated with the enhancer part. Reference can be made to EP-A—260 148, EP-A—323
597, US. Pat. Nos. 5,168,062, 839, and 4,968,615, as well as to PCT Application No
WO87/03905. The CMV-IE promoter is ageously a human CMV-IE (Boshart M. et al., Cell.,
1985, 41, 521-530) or murine CMV-IE.
In more general terms, the promoter has either a viral or a cellular origin. A strong viral
promoter other than CMV-IE that may be usefully employed in the practice of the invention is the
early/late promoter of the SV40 virus or the LTR promoter of the Rous sarcoma virus. A strong cellular
promoter that may be usefully employed in the practice of the invention is the promoter of a gene of
the cytoskeleton, such as e.g. the desmin promoter (Kwissa M. et al., Vaccine, 2000, 18, 344),
or the actin promoter (Miyazaki J. et al., Gene, 1989, 79, 269-277).
Functional sub fragments of these promoters, i.e., portions of these promoters that maintain
an adequate promoting activity, are included within the present invention, e.g. ted CMV-IE
promoters according to PCT Application No. WO98/00166 or US. Pat. No. 6,156,567 can be used in
the practice of the invention. A promoter in the practice of the invention consequently includes
derivatives and sub fragments of a full-length promoter that maintain an te promoting activity
and hence function as a promoter, preferably promoting ty substantially similar to that of the
actual or full-length promoter from which the derivative or sub fragment is derived, e.g., akin to the
activity of the truncated CMV-IE promoters of U.S. Pat. No. 6,156,567 to the activity of full-length
CMV-IE promoters. Thus, a CMV-IE promoter in the practice of the invention can comprise or t
essentially of or consist of the promoter n of the ength promoter and/or the enhancer portion
of the full-length promoter, as well as derivatives and sub fragments.
Advantageously, the plasmids comprise or consist essentially of other expression control
elements. It is ularly advantageous to incorporate stabilizing sequence(s), e.g., intron
sequence(s), preferably the first intron of the hCMV-IE (PCT Application No. WO89/01036), the intron
ll of the rabbit B—globin gene (van Ooyen et al., Science, 1979, 206, 337-344).
As to the polyadenylation signal (polyA) for the plasmids and viral vectors other than
poxviruses, use can more be made of the poly(A) signal of the bovine growth hormone (bGH) gene
(see U.S. Pat. No. 5,122,458), or the poly(A) signal of the rabbit B-globin gene or the poly(A) signal of
the SV40 virus.
According to another embodiment of the invention, the expression vectors are expression
vectors used for the in vitro expression of ns in an appropriate cell system. The expressed
proteins can be harvested in or from the e supernatant after, or not after secretion (if there is no
secretion a cell lysis typically occurs or is performed), optionally concentrated by concentration
methods such as ultrafiltration and/or ed by purification means, such as affinity, ion ge or
gel tion-type chromatography methods.
It is understood to one of skill in the art that conditions for culturing a host cell varies according
to the particular gene and that routine mentation is necessary at times to determine the optimal
ions for culturing rabies glycoprotein ing on the host cell. A “host cell” denotes a
prokaryotic or eukaryotic cell that has been genetically altered, or is capable of being genetically
altered by administration of an exogenous polynucleotide, such as a recombinant plasmid or vector.
When referring to genetically altered cells, the term refers both to the originally altered cell and to the
progeny thereof.
Polynucleotides comprising a desired sequence can be inserted into a le cloning or
expression vector, and the vector in turn can be introduced into a suitable host cell for replication and
amplification. Polynucleotides can be introduced into host cells by any means known in the art. The
vectors containing the polynucleotides of interest can be introduced into the host cell by any of a
number of appropriate means, including direct uptake, endocytosis, transfection, f-mating,
electroporation, transfection employing calcium chloride, um chloride, calcium phosphate, DEAE-
dextran, or other substances; rojectile bombardment; lipofection; and infection (where the vector
is infectious, for instance, a retroviral ). The choice of introducing vectors or polynucleotides will
often depend on features of the host cell.
In an advantageous embodiment, the invention provides for the administration of a
therapeutically effective amount of a formulation for the delivery and sion of rabies glycoprotein
in a target cell. Determination of the therapeutically effective amount is e mentation for one
of ordinary skill in the art. In one embodiment, the formulation comprises an expression vector
comprising a polynucleotide that expresses rabies glycoprotein and a pharmaceutically or veterinarily
acceptable carrier, vehicle or excipient. In an advantageous embodiment, the pharmaceutically or
narily able carrier, vehicle or excipient facilitates transfection and/or improves preservation
of the vector or protein.
The pharmaceutically or veterinarily acceptable carriers or vehicles or excipients are well
known to the one skilled in the art. For example, a pharmaceutically or narily acceptable carrier
or vehicle or excipient can be a 0.9% NaCl (e.g., saline) solution or a phosphate buffer. Other
4o pharmaceutically or veterinarily acceptable carrier or vehicle or excipients that can be used for
methods of this ion include, but are not limited to, poly-(L-glutamate) or polyvinylpyrrolidone. The
ceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or
combination of compounds facilitating the administration of the vector (or protein expressed from an
inventive vector in vitro); advantageously, the carrier, vehicle or excipient may facilitate transfection
and/or improve preservation of the vector (or protein). Doses and dose volumes are herein discussed
in the general description and can also be determined by the skilled artisan from this disclosure read in
conjunction with the knowledge in the art, without any undue experimentation.
Among these cationic lipids, preference is given to DMRIE (N-(2-hydroxyethyl)—N,N-dimethyl-
2,3-bis(tetradecyloxy)—1-propane ammonium; WO96/34109), advantageously associated with a neutral
lipid, advantageously DOPE (dioleoyl-phosphatidyl-ethanol amine; Behr J. P., 1994, Bioconjugate
Chemistry, 5, 382-389), to form DMRIE-DOPE.
ageously, the plasmid mixture with the adjuvant is formed extemporaneously and
ageously contemporaneously with administration of the preparation or shortly before
administration of the preparation; for instance, shortly before or prior to administration, the plasmid-
adjuvant mixture is formed, advantageously so as to give enough time prior to stration for the
mixture to form a complex, e.g. between about 10 and about 60 minutes prior to stration, such
as approximately 30 minutes prior to administration.
When DOPE is present, the DOPE molar ratio is advantageously about 95: about 5 to
about 5:about 95, more advantageously about 1: about 1, e.g., 1:1.
The DMRIE or DMRIE-DOPE adjuvant:plasmid weight ratio can be between about 50: about 1
and about 1: about 10, such as about 10: about 1 and about t 5, and advantageously about 1:
about1 and about 1: about 2, e.g., 1:1 and 1:2.
In a specific embodiment, the pharmaceutical composition is directly stered in vivo, and
the encoded product is expressed by the vector in the host. The methods of in vivo delivery a vector
encoding rabies rotein (see, e.g., US. Pat. No. 693; patent publications EP 1052286, EP
1205551, US. patent publication 20040057941, WO 9905300 and Draghia—Akli et al., Mol Ther.
December 2002;6(6):830-6; the disclosures of which are incorporated by reference in their entireties)
can be modified to deliver a rabies glycoprotein of the present invention to a dog. The in vivo delivery
of a vector enooding rabies glycoprotein described herein can be accomplished by one of ordinary skill
in the art given the ngs of the above-mentioned references.
Advantageously, the pharmaceutical and/or therapeutic compositions and/or formulations
according to the ion comprise or t essentially of or consist of an effective quantity to elicit a
eutic response of one or more expression vectors and/or polypeptides as discussed herein; and,
an effective quantity can be determined from this sure, including the nts incorporated
herein, and the knowledge in the art, without undue experimentation.
One skilled in the art can determine the effective plasmid dose to be used for each
immunization or vaccination protocol and species from this disclosure and the knowledge in the art.
In an advantageous embodiment, the pharmaceutical and/or therapeutic compositions and/or
formulations according to the invention are administered orally. In a ularly advantageous
4o embodiment, the oral itions are administered as a bait drop. For example, the bait drop can
comprise a polymer cube (1.25 inches by 0.75 inches) that is hollow. A sachet, or plastic packet,
containing the rabies vaccine can be inserted into the hollow area of the bait and sealed with wax. The
bait is attractive to raccoons and other wildlife, and strong enough to withstand distribution from
nes flying at low altitude (e.g., about 500 feet). When a raccoon or other wildlife finds the bait and
bites into it, the sachet ruptures, ng the vaccine to enter the raccoon’s mouth. Raccoons and
other wildlife then become vaccinated against rabies by this oral route.
Also in connection with such a eutic ition, from the disclosure herein and the
knowledge in the art, the skilled artisan can determine the number of strations, the
administration route, and the doses to be used for each injection protocol, without any undue
experimentation.
In some embodiments, non-ionic hydrophilic surfactants having a high hydrophilic-lipophilic
balance (HLB) value may be added to the disclosed formulations. This group comprises ethoxylated
fatty acid monoesters of sorbitan (in particular 20 ethoxyl groups) (e.g. ethoxylated sorbitan
monolaurate such as TWEEN 20®, ethoxylated sorbitan monopalmitate such as TWEEN 40®,
ethoxylated sorbitan monostearate ( such as TWEEN 60®, ethoxylated sorbitan monooleate such as
TWEEN 80®, ethoxylated fatty alcohols (in particular 15-30 l groups) (e.g. BRIJ 78®, BRIJ 98®,
BRIJ 721®), lated fatty acids (in ular 15-30 ethoxyl groups) (e.g. MYRJ 49®, MYRJ 51®,
MYRJ 52®, MYRJ 53®), non-ionic block-copolymers (e.g. polyoxyethylene/ polyoxypropylene
copolymer (POE-POP), such as LUTROL F127®, LUTROL F68®), and combinations thereof.
The disclosed formulation may include fatty acid esters of an (e.g. sorbitan monolaurate,
like SPAN 20®, sorbitan monopalmitate, such as SPAN 40®, sorbitan monostearate, such as SPAN
60®, sorbitan tristearate, such as SPAN 65®, sorbitan monooleate, like SPAN 80®, sorbitan trioleate,
like SPAN 85®, sorbitan monoisostearate, such as ARLACEL 987®, sorbitan isostearate, such as
CRILL 6®), fatty acid esters of mannide (e.g. MONTANIDE 80®, mannide eate (such as
ARLACEL A®), mannide dioleate, mannide trioleate, mannide tetraoleate), ethoxylated fatty acid
esters of mannide (2, 3 or 4 ethoxyl groups) (e.g. MONTANIDE 888®, MONTANIDE 103®,
ethoxylated mannide monooleate, ethoxylated e dioleate, ethoxylated mannide trioleate,
lated mannide tetraoleate), and combinations thereof. The fatty acid may be oleate, palmitate,
stearate, isostearate, laurate and combinations thereof.
In some embodiments, oils may be added to the disclosed formulations, including mineral oils,
such as paraffin oil including isoparaffinic oil and/or naphtenic oil, squalane, pristane, polyisobutene
oil, hydrogenated polyisobutene oil, polydecene oil, polyisoprene oil, polyisopropene oil and the like.
Such oils may, for example, be those marketed under the name "MARCOL 52®" or “MARCOL 82®”
ced by Esso, France) or "DRAKEOL 6VR®" or "DRAKEOL 5®" "DRAKEOL 7®" (produced by
Penreco, USA), “CLEAROL®“ ced by Sonneborn, USA), “Paraffin Oil Codex AABZ®” ced
by Aiglon, France), BLANDOL (produced by Sonneborn, USA), ONDINA 915 (produced by Shell, UK).
The oil may also be a e of oils comprising at least 2 oils selected among the oils described
herein, and in any proportion. The e of oils may also comprise at least one oil ed among
the oils described above and at least one vegetable oil, and this vegetable oil represents from about
40 0.1% to about 33% of the oily phase, preferably from about 10% to about 25% v/v. These vegetable
oils are unsaturated oils rich in oleic acid that are biodegradable and preferably liquid at the storage
temperature (about +4 °C.) or at least make it possible to give emulsions that are liquid at this
ature. For example the vegetable oil may be groundnut oil, nut oil, sunflower oil, safflower oil,
soya oil, onager oil and the like.
Generally, the present invention envisions using a viscous aqueous solution comprising a
suitable nary or pharmaceutically acceptable vehicle, excipient, or diluent including, but not
limited to, sterile water, physiological saline, glucose, buffer and the like. The vehicle, excipient or
diluent may also e polyols, glucids or pH ing agents. The e, excipient or diluent may,
for e, also comprise amino acids, peptides, antioxidants, bactericide, and iostatic
compounds.
In a particular embodiment, the formulations are suitable oral baits useful for immunizing
wildlife, including raccoons, foxes, and the like.
Optionally other nds may be added as co-adjuvants to the emulsion, ing, but not
limited to, alum; CpG oligonucleotides (ODN), in particular ODN 2006, 2007, 2059, or 2135 (Pontarollo
RA et al., Vet. Immunol. Immunopath, 2002, 84: 43-59; Wernette C.M. et al., Vet. Immunol.
Immunopath, 2002, 84: 223-236; Mutwiri G. et al., Vet. Immunol. Immunopath, 2003, 91: 89-103);
polyA-polyU (“Vaccine Design The Subunit and Adjuvant Approach”, edited by Michael F. Powell and
Mark J. Newman, Pharmaceutical Biotechnology, 6: 03); dimethyldioctadecylammonium bromide
(DDA) (“Vaccine Design: The Subunit and Adjuvant Approach”, edited by Michael F. Powell and Mark
J. Newman, Pharmaceutical Biotechnology, volume 6: 157), N,N-dioctadecyl-N’,N’-bis(2—hydroxyethyl)
propanediamine (such as AVRIDINE®) (lbid, p. 148), or carbomer.
The immunogen or antigen suitable for use in the present invention may be selected from the
group consisting of inactivated pathogens, attenuated ens, immunogenic sub-units (e.g.
proteins, polypeptides, peptides, epitopes, haptens), or recombinant sion vectors, including
plasmids having immunogenic s. In one embodiment of the present invention, the immunogen is
an inactivated or killed microorganism.
In a preferred embodiment, the gen is a rabies antigen, for example the vaccinia-
vectored rabies antigens of RABORAL VRG (Merial Limited).
The invention will now be further described by way of the following non-limiting examples.
Example 1
Virucidal Activity Assay: Method for Screening Suitable Adjuvants
Prior to testing new adjuvants on animals, the inventors developed an in vitro dal activity
assay, to make sure ial adjuvanting compounds did not have a deleterious effect on the viral-
vector vaccine component. This ty assay was particularly useful for screening candidate
adjuvants that could be used in formulation with ia—vectored RABORAL V-RG®. Mixtures of
s candidate adjuvants and RABORAL V-RG® were tested for their compatibility on Vero cells.
Candidate adjuvants included CARBOPOL® and various forms of chitosan.
Viral Plaque assays were performed using Vero cell monolayers in 6-well tissue culture plates
40 (Greiner, Monroe, NC). RABORAL V-RG® was obtained directly from the cturer, Merial,
Limited (Athens, Georgia, USA). Serial 1:10 dilutions of RABORAL V-RG® alone, (candidate 1
adjuvant) + RABORAL V-RG®, and (candidate 2 adjuvant) + RABORAL V-RG® were made and
allowed to incubate at 37°C for 20 min before addition to Vero cells. One hundred microliters of each
dilution was plated per well in duplicate and incubated for 1 hour and 45 min at 37°C to allow the virus
to adhere to the cell yer. After the tion, 2.5 ml of a 0.5% agarose overlay containing 1x
RPMI, 50 pg/ml gentamycin, and 250 ng/ml amphotericin B was added over the top of the cells and
the plates were returned to the incubator. After 24 hr, a second overlay was prepared as before, but
with the addition of 30 ug/ml neutral red and was applied over the top of the previous overlay. The
plates were monitored for plaque formation and counted 2 days after inoculation when the plaques
were e as clear spots on the . The reciprocal of dilutions with numbers of plaques in a
countable range (between 10-100 plaques) were used to calculate viral titer as PFU/mL. It is
contemplated by the inventors that candidate nts with the lowest virucidal ty, as measured
by this assay, should be advanced to model animal studies and/or target animal studies.
Example 2
Chitosan Adjuvants
Chitin is a polymer that naturally occurs in crustaceans, insects, and mushrooms (Seferian,
PG et al. 2001). When chitin is deacetylated, it becomes chitosan, a natural cationic polysaccharide
that is highly biodegradable, has a low toxicity ian, PG; Dodane, V), and has a relatively neutral
pH (6.8-7.2) when combined with a phosphate buffer solution. As chitosan is neutralized, it forms a
gelatinous precipitate, and its strong mucoadhesive properties increase the bioavailability of a vaccine
or drug (Baudner, BC et al. 2004). In addition to acting as a thickener, chitosan is also an adjuvant.
Chitosan effectively disrupts tight junctions in the mucosa, enhancing transport and tion of
drugs and vaccines across the lial barrier (Van der Lubben, IM et al.; Smith, J et al.; Van der
MenNe, SM et al.). After crossing the epithelium, chitosan stimulates immunity by activating
macrophages and cytotoxic T-lymphocytes (van der , IM et al. 2001). Chitosan is essentially
non-lethal to animals as its 50% lethal dose (LD50) when given orally to mice was 16 g/kg, a LD50
lower than e (Arai, K et al.; Dodane, V et al.).
Other variants of chitosan are known in the art, including TMC, a chitosan derivative that
ts similar utility as a thickener and drug/vaccine adjuvant (Van der Merwe et al., SM; LueBen, HL
et al.; Van der Lubben, IM et al., 2001). TMC is more soluble at neutral pH than chitosan (Kotze AF et
al. 1997) but maintains the immunogenic and adhesive properties of chitosan; thus ting that this
nd may be superior to chitosan under physiologic conditions.
Methods. TMC was produced from commercially available an (Sigma Aldrich, St. Louis,
Missouri, USA) using an emulsion of 2% chitosan and 2% acetic acid. The pH of the emulsion was
neutralized with NaOH and the preparation was then dried. The resulting paste was used directly to
ate solutions for this study. Stock solutions of TMC and chitosan were made with RPMI (Sigma,
St. Louis, MO) as the diluent. The TMC solution was made to a stock tration of 5%. The
limited solubility of chitosan dictated the concentration of the solution, so the stock concentration for
chitosan was 1%. To get chitosan to dissolve, HCl was added dropwise to make a more acidic
on as the mixture was stirred until the chitosan was no longer visible. After the solutions were
40 made, they were sterilized by autoclaving to eliminate contamination that could interfere with the in
vitro assays (described above) and/or interfere with immunization.
Because the effect of chitosan and TMC on RABORAL V-RG® vaccinia vector viability was
unknown, mixtures of L V-RG® combined with chitosan or TMC were tested according to the
method of Example 1 to determine whether the viability of the virus was affected ly by these
compounds. Chitosan was prepared as a 1% stock solution and TMC was prepared as a 5% stock
solution. L V-RG® suspension was mixed in equal volumes with RPMI (control), TMC or
chitosan as planned for the in vivo study. Final concentrations tested ranged from 0.25% - 0.5% for
chitosan and 0.05% - 2.5% for TMC. According to the results summarized in Table 1, the final vaccine
titer was for RABORAL V-RG® alone was similar to the titer obtained when RABORAL V-RG® was
combined with either chitosan or TMC.
Table 1. Plaque assay evaluation of RABORAL V-RG® viability when ed with adjuvants.
Volume Final titer Final
Volume of
RABORAL V- RABORAL concentration_
Formulation name. adjuvant stock*.
RG®¢ V-RG® l adjuvant_
(mL)
(mL) (TCID50) (%)
RABORAL V-RG®
RABORAL V-RG®
+ chitosan
RABORAL V-RG®
+TMC
#Stock titer of RABORAL V-RG® = 107.4 TCID50/mL
*Chitosan stock = 1% and TMC stock = 5%
Example 2
Vaccination of Raccoons using an-adjuvanted Vaccinia-vectored Rabies Vaccines
RABORAL V-RG® titers were also ated using TCID50. Briefly, Vero cells were
nized and counted using a hemacytometer and added to 96-well plates with 4x104 cells per well
in R5 media (100 pl RPMI (Hyclone, Logan, UT, USA) 5% fetal bovine serum (Hyclone, Logan, UT.
USA). Vero cells were incubated at 37°C and 5% C02 for 24 hr. Serial 1:10 dilutions of RABORAL V-
RG®, chitosan + RABORAL V-RG®, and TMC + RABORAL V-RG® were made in R5 media and
dilutions were plated at 100 pl per well in replicates of 8 wells per dilution. Results were ined
by visual examination with an ed phase contrast microscope looking for cytopathic effect (CPE)
after 1 week incubation at 37°C and 5% C02. Any well with evidence of CPE was considered positive
for infection. TCID50 titers were calculated using the Spearman-Karber formula.
Table 2. Final e and adjuvant formulations delivered orally to raccoons
Adjuvant Concentration of Final vaccine titer
adjuvant (PFU)
None (RABORAL V- 5x105
RG® only)
Chitosan 0.25 % 1 x 106
TMC 2.5 % 8 x 105
TMC 0.5 % 2 X 105
TMC 0.25 % 2 X 105
TMC 0.05 % 3 X 105
Forty raccoons were trapped using medium sized Tomahawk® traps in r County,
Colorado. ns were individually housed in 3 x 3 x 2.5 m pens that included den boxes and
enrichment structures at the USDA National Wildlife Research Center’s Outdoor Animal Research
Facility for the duration of the study. When accessioned into the captive population each raccoon was
ted for health, administered anthelmintic medication, vaccinated for distemper with the GALAXY
D® vaccine (Schering-Plough Animal Health Corporation, Boxmeer, The Netherlands), and an AVID
microchip pit tag (Avid Identification Systems, Inc, Norco, CA) was placed subcutaneously between the
shoulder blades. Blood was also collected at this time to confirm baseline rabies VNA titers. Raccoons
were tined for a minimum of 14 days prior to the start of the study.
Three vaccine formulations were prepared in 2 mL dosages as follows: 2 mL L V-
RG® alone, 1mL RABORAL V-RG® + 1mL of 1% chitosan, and 1mL RABORAL V-RG® + 1mL of 5%
TMC (Table 2). Seronegative raccoons were placed into one of four treatment groups, chitosan +
RABORAL V-RG® (n=12), TMC + RABORAL V-RG® (n=12), RABORAL V-RG® only (n=12), or no
vaccine (n= 4). After mild sedation with 10mg/kg ketamine HCl and 2 mg/kg xylazine (Deresienski, DT
et al. 1989) blood was ted from each raccoon and 2 ml of the corresponding vaccine mixture was
delivered via needleless syringe into the mouth of each . Raccoons were able to swallow the
e, allowing the volume of the vaccine consumed to be confirmed. The day of vaccination is
considered 0 days post inoculation (dpi). On 90 dpi all raccoons ed a 2 mL booster dose of the
appropriate vaccine ation or placebo vaccine delivered orally. To follow rabies VNA
pment, animals were anesthetized and blood was collected via venipuncture of the jugular vein
on days 4, 14, 21, 28, 60, 90, 104, 126 dpi. Rabies VNA were measured by the Rapid Fluorescent
Focus Inhibition Test (RFFIT) at the Centers for Disease Control and Prevention, Atlanta, GA. Serum
dilutions up to 1:56 were tested.
A summary of raccoon neutralizing antibody responses by treatment groups were compared
by ic regression with significance determined with a p-value < 0.1, due to the conservative
sample sizes within each treatment group. Rabies VNA were analyzed using a generalized linear
model ed measures analysis of variance, with significance accepted at alpha = 0.05. All
treatments and controls were compared at each time step using Tukey’s Studentized Range Test.
Table 3 rates the number of raccoons that responded to each vaccine by producing
neutralizing dies after the primary and boost vaccination. After the initial vaccination, 92%
raccoons vaccinated with TMC + RABORAL V-RG® responded to the vaccine with rabies VNA > 0.5,
the threshold suggested for wild ns by (Moore, SM et al.). While only 66% of raccoons
vaccinated with RABOARL V-RG® had rabies VNA levels > 0.5. When comparing the number of
raccoons that produced rabies VNA, animals ated with TMC + RABORAL V-RG® performed
marginally better than animals inoculated with RABORAL V-RG® alone ue =0.066).
Table 3: Summary of the number of individual raccoons responding to RABORAL V-RG® vaccine
formulations.
Treatment # of raccoons with Rabies # of raccoons with Rabies
VNA >0.5 prior to boost at VNA >0.5 after boost at 90
90 days (n) days (n)
RABORAL V-RG® 8 (12) 11 (11)
Chitosan + RABORAL V-RG® 2 (12) 5 (11)
TMC + RABORAL V-RG® 11 (12) 12 (12)
Rabies VNA titers among the ent vaccine combinations were significantly different (F
3,32: 9.07, P < 0.001). shows the s in average rabies VNA titers over the course of the
study. The chitosan + RABORAL V-RG® vaccine was consistently less ive at eliciting a humoral
immune response than the RABORAL V-RG® vaccine and TMC + RABORAL V-RG® vaccine s
Studentized Range Test demonstrated that after 60 dpi, rabies VNA responses from raccoons
receiving TMC + RABORAL V-RG® were consistently higher than the raccoons that received chitosan
+ RABORAL V—RG®, but not significantly different than the RABORAL V-RG® only treatment group
(.
These data present for the first time evidence that mucosal adjuvants being sfully
applied to veterinary vaccine formulations. Surprising trimethylated chitosan (TMC) significantly
outperformed an as an effective adjuvant for RABORAL V-RG®, though both appeared to exert
useful adjuvanting s. After a dose of chitosan + RABORAL V-RG® only 16.7% of individuals
produced rabies VNA and even after a r vaccination with the same mixture only 45.5% of
raccoons had detectable rabies VNA. One dose of the traditional RABORAL V-RG® formulation was
enough to produce rabies VNA in 66.7% (8/12) of individuals and after a booster vaccination rabies
VNA titers were detected in 100% ) raccoons. However, for wildlife oral rabies vaccination
(ORV) campaigns, booster vaccinations are not always possible. Because a single dose of TMC +
RABORAL V-RG® mixture surprisingly induced detectable rabies VNA in 92% (11/12) of tested
raccoons, the adjuvanted vaccine baits described herein should effectively compensate for the lack of
ability to consistently deliver a booster dose to all wildlife animals.
TMC also altered the physical ties of the vaccine, which may be very ant when
designing ORV programs for raccoons. TMC produced a viscous vaccine mixture that may help
prevent vaccine spillage in the field. One reason RABORAL V-RG® may be more effective in foxes
and coyotes than raccoons could be the way ent species handle the baits. For instance, foxes
and s tend to pick up a compete bait with their mouth, and masticate the bait, thus releasing the
entire dose of vaccine into their mouths. Contrary to this feeding gy raccoons tend to grasp the
e sachet on the ground and bite only small portions at a time, allowing the open sachet to leak,
and vaccine spillage to occur (B. Schmidt unpublished data). Pen trials using placebo liquids contained
in baits and sachets repeatedly show raccoons spilling >50% of the liquid contents of the sachet and
the same has been documented in skunks (Grosenbaugh, DA et al. 2007; Jojola, SM et al. 2007).
When volumes nearing 50% of the contents of the sachet are spilled the likelihood of successful
vaccination is greatly decreased. While not yet evaluated in the field, the viscosity that TMC adds to
the traditional RABORAL V-RG® vaccine may prevent or reduce spillage and increase the likelihood
that a raccoons will e the entire dose of vaccine.
The instant disclosure provides strong evidence of TMC’s ability to improve the immunogenic
effects of RABORAL V-RG® using only 1/2 of the traditional RABORAL V-RG® vaccine dose while
creating a more viscous suspension, which may result in significant improvement in the vaccination of
animals, including ns, in the field. Improvements in the delivery and immunogenicity of
RABORAL V-RG® to certain fe species is crucial since obtaining a threshold affect for herd
immunity is necessary to curtail the spread of rabies in wildlife reservoirs.
References
WHO. Rabies vaccines: WHO on paper. Weekly epidemiological record. No. 32,
2010;85. p. 209—320.
Hethcote, HW. An immunization model for a heterogeneous population. Theoretical Population
Biology 1978; 14:338—349.
Slate, D., Algeo, TP, Nelson, KM, et al. Oral rabies vaccination in north America: unities,
xities, and challenges. PLOS 2009; 3(13)1-9, e529.
Fearneyhough MG, Wilson PJ, Clark KA, et al. Results of an oral rabies vaccination program
for coyotes. Journal of the American nary Medical Association 1998; 212(4):498-502.
Sidwa TJ, Wilson PJ, Moore, GM, et al. Evaluation of oral rabies ation programs for
control of rabies epizootics in coyotes and gray foxes: 1995—2003. Journal of the an Veterinary
l Association 2005; 227(5):785-792.
baugh, DA, Maki, JL, cht CE, Wall DK. Rabies challenge of captive striped
skunks (Mephitis mephitis) following oral administration of a live vaccinia—vectored rabies vaccine.
Journal of Wildlife Diseases 2007; 42(1) 124-128.
Jojola, SM, Robinson, SJ, Vercauteren, KC. Oral rabies vaccine (ORV) bait uptake by captive
skunks. Journal of Wildlife Disease 2007; 42(1): 97-106.
Schijns VE. Immunological concepts of vaccine adjuvant activity. Current Opinions in
Immunology 2000; 12(4):456-463.
Seferian, PG, Martinez, ML. Immune stimulating activity of two new chitosan ning
adjuvant formulations. Vaccine 2001; 19:661-668.
Dodane V., Amin Kahn M., Men/Vin, J.R. Effect of chitosan on epithelial permeability and
40 structure. International Journal of Pharmaceutics 1999; 182:21-32.
Baudner, BC, Verhoef, JC, Junginger, HE, et al. Mucosal nts and ry systems for
oral and nasal vaccination. Drugs of the Future 2004; 29(7): 721-732.
van der Lubben, IM, Verhoef, JC, Borchard, G., et al., Chitosan for mucosal vaccination.
Advanced Drug ry Reviews 2001; 52: 139-144.
Smith, J., Wood, E., Dornish, M. Effect of an on lial cell tight ons.
Pharmaceutical Research 2004; 43-49.
van der Merwe SM, Verhoef, JC, jden, JHM, et al. Trimethylated chitosan as polymeric
absorption enhancer for improved peroral delivery of peptide drugs. European Journal of
Pharmaceutical Sciences 2004; 58: 225-235.
Arai, K, Kinumaki, T, , T. Toxicity of chitosan. Bull. Tokai. Region Fish. Res. Lab. 1968;
56:89-94.
Dodane V., Vilivalam, VD. Pharmaceutical applications of chitosan. PSIT 1998; 1(16):246-253.
LueBen, HL, de Leeuw, BJ, Langemeyer, MWE., et al. hesive polymers in peroral
peptide drug delivery. Vl. Carbomer and chitosan improve the intestinal tion of the peptide drug
buserelin. Pharmaceutical Research 1996; 13(11): 1668-1672.
van der Lubben, IM, Verhoef, JC, Borchard, G., et al. Chitosan and its derivatives in mucosal
drugs and vaccine delivery. European Journal of Pharmaceutical Sciences 2001; 14:201-207.
Kotze AF, LueBen HL, de Leeuw, BJ, et al. N-trimethyl chitosan chloride as a potential
absorption enhancer across mucosal surfaces: In vitro evaluation in intestinal epithelial cells (Caco—2).
Pharmaceutical research 1997; 14(9): 1197-1202.
Deresienski, DT, cht, CE. Yohimbine reversal of ketamine-xylazine immobilization of
raccoons (Procyon lotor); Journal of Wildlife Diseases, 1989, 25(2):169-174.
Moore, SM, Hanlon, CA. Rabies specific antibodies: Measuring surrogates of protection
against fatal disease. PLOS Neg Trop Dis 2010. 4(3)e595.
Brown, LJ, R.C. Rosatte, RC, Fehlner—Gardiner C, et al. l of Wildlife Diseases 2011;
47(1):182—194.
********
Having thus described in detail preferred embodiments of the present invention, it is to be
understood that the invention defined by the above paragraphs is not to be limited to particular details
set forth in the above description as many apparent variations thereof are possible without departing
from the spirit or scope of the present invention.
Claims (24)
1. A single-dose adjuvanted Rabies virus e composition comprising an attenuated
recombinant Orthopox or Avipox viral vector and a methylated chitosan derivative adjuvant, wherein
the vector is capable of expressing in an animal host one or more Rabies virus immunogens, and
n the presence of the adjuvant is associated with both increased viscosity, and increased
protective cy against subsequent experimental or natural challenge with a virulent Rabies virus,
as compared to an otherwise equivalent composition wherein the nt has been omitted.
2. The composition of claim 1, which is an oral vaccine.
3. The composition of claim 1 or 2 wherein the vector is an Avipox virus.
4. The composition of claim 3 wherein the vector is a Vaccinia virus.
5. The composition of claim 1 wherein the adjuvant is trimethylated an (TMC).
6. The composition of claim 5 wherein the TMC is present in an amount between 0.25 and 5%
w/v of the composition.
7. The composition of claim 6, wherein the TMC is t in an amount between 0.25 and 2.5%
w/v of the composition.
8. The composition claim 7, wherein a single dose of the ition is adequate to protect from
subsequent natural or experimental virulent Rabies virus challenge greater than 80% of the animals
ing the single dose, and greater than 95% of the animals receiving a second, booster dose.
9. The composition of claim 4, wherein the vector is ia virus comprises a rabies surface
glycoprotein gene and wherein the TMC is present in an amount of about 2.5% w/v.
11. A method of eliciting an immune response in a non-human animal comprising administering
the composition of any one of the ing claims in an amount effective for eliciting an immune
se in the animal.
12. The method of claim 11 wherein the vector comprises a modified live Vaccinia virus.
13. The method of claim 11 wherein the vector comprises the rabies surface glycoprotein gene.
14. The method according to claim 13, wherein the surface glycoprotein gene is rabies
glycoprotein G.
15. The method of claim 14 wherein the rabies glycoprotein G is derived from an ERA strain.
16. The method of claim 12 wherein the vaccinia virus is a Copenhagen strain.
17. The method of claim 12 wherein the ia virus has a tk- phenotype.
18. The method of claim 12 wherein the vaccinia virus has a tk- phenotype.
19. The method of any one of claims 12 to 18 n the modified live vaccinia virus is the
Copenhagen strain and has a tk- phenotype and further comprises the rabies virus glycoprotein G
encoded therein.
20. The method of any one of claims 11 to 18 wherein the administration is oral.
21. The method of claim 20 wherein the oral administration is by a bait drop.
22. The method of any one of claims 11 to 21 wherein the non-human animal is a raccoon.
23. Use of the composition of any one of claims 1 to 9 in the manufacture of a medicament for
eliciting an immune response in an .
24. The composition according to any one of claims 1 to 9, or the method according to any one of
claims 11 to 22, or the use according to claim 23, substantially as described herein with nce to
the figures and/or examples, excluding comparative examples.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161477548P | 2011-04-20 | 2011-04-20 | |
US61/477,548 | 2011-04-20 | ||
PCT/US2012/034366 WO2012145577A1 (en) | 2011-04-20 | 2012-04-20 | Adjuvanted rabies vaccine with improved viscosity profile |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617072A NZ617072A (en) | 2016-07-29 |
NZ617072B2 true NZ617072B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU762479B2 (en) | Live recombined vaccines injected with adjuvant | |
KR102526219B1 (en) | Fmdv recombinant vaccines and uses thereof | |
Blancou et al. | Oral vaccination of the fox against rabies using a live recombinant vaccinia virus | |
US20080014221A1 (en) | Mycoplasma hyopneumoniae vaccine | |
US10493144B2 (en) | Recombinant adenovirus vectored FMDV vaccines and uses thereof | |
US10010499B2 (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
US20170087244A1 (en) | Canine Parvovirus (CPV) Virus-like Particle (VLP) Vaccines and uses thereof | |
US8168200B2 (en) | Vaccine against african horse sickness virus | |
TWI744260B (en) | Fmdv and e2 fusion proteins and uses thereof | |
US9216213B2 (en) | Adjuvanted rabies vaccine with improved viscosity profile | |
US20050282210A1 (en) | Vaccination of skunks and/or mongooses against rabies | |
NZ617072B2 (en) | Adjuvanted rabies vaccine with improved viscosity profile | |
US20140271708A1 (en) | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G | |
AU2014218358B2 (en) | Vaccine against african horse sickness virus | |
WO2013138776A1 (en) | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g | |
AU2003246343B2 (en) | Live recombined vaccines injected with adjuvant | |
MXPA00008524A (en) | Live recombined vaccines injected with adjuvant |